Molecular predictors of response to pembrolizumab in thymic carcinoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34622229.
- Also identified by DOI 10.1016/j.xcrm.2021.100392 and PMC identifier 8484507.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options are limited after failure of platinum-based chemotherapy. We previously performed a single-center phase II study of pembrolizumab in patients with advanced thymic carcinoma, showing a 22.5% response rate. Here, we characterize the genomic and transcriptomic profile of thymic carcinoma samples from 10 patients (5 non-responders versus 5 responders) in this cohort, with the main aim of identifying potential predictors of response to immunotherapy. We find that expression of <i>PDL1</i> and alterations in genes or pathways that correlated with PD-L1 expression (<i>CYLD</i> and <i>BAP1</i>) could be potential predictors for response or resistance to immunotherapy in patients with advanced thymic carcinoma. Our study provides insights into potential predictive markers/pathways to select patients with thymic carcinoma for anti-PD-1 immunotherapy.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Thymoma
- Thymus Neoplasms